https://www.openbell.ai/ 2026-09-30T11:50:02.813Z hourly 1.0 https://www.openbell.ai/support 2026-09-30T11:50:02.813Z monthly 0.7 https://www.openbell.ai/privacy 2026-09-30T11:50:02.813Z monthly 0.5 https://www.openbell.ai/terms 2026-09-30T11:50:02.813Z monthly 0.5 https://www.openbell.ai/feed.json 2026-09-30T11:50:02.813Z hourly 0.8 https://www.openbell.ai/news/HPE:1790768907829 2026-09-30T11:48:27.829Z daily 0.9 https://cdn.brandfetch.io/HPE/w/400/h/400?c=1idopYfmtR7ZKg8QMud HPE Receives $1.2B Order From Vultr To Install AMD Helios AI Rack; Raises FY27 Networking Segment Revenue Growth Guidance Between High Teens To Low-20% HPE has secured a $1.2 billion order from Vultr to deploy its AMD Helios AI Rack systems, marking the first order for this new technology. In conjunction with this announcement, HPE has raised its FY27 Networking segment revenue growth guidance to between high teens and low-20s percent, with an expected operating margin in the mid-to-high 20s percent range. To address strong demand and supply constraints, HPE has doubled its networking supply purchase commitments in the third quarter of FY26. https://www.openbell.ai/news/HPE:1790768905586 2026-09-30T11:48:25.586Z daily 0.9 https://cdn.brandfetch.io/HPE/w/400/h/400?c=1idopYfmtR7ZKg8QMud HPE Receives $1.2B Order From Closely Held Cloud Infrastructure Provider Vultr To Deploy AMD Helios AI Racks At Its U.S. Cloud Data Centers Hewlett Packard Enterprise (HPE) has secured a $1.2 billion order from Vultr, a cloud infrastructure provider, for the deployment of AMD Helios AI racks at its U.S. data centers. This marks HPE's first order for the AMD Helios system, which is designed for high-performance AI workloads. The collaboration builds on nearly three years of partnership between Vultr and Juniper Networks, now part of HPE, and aims to address the growing demand for AI infrastructure. The Helios racks feature advanced AMD technology, including 72 GPUs per rack, optimized for high-density model training and inference. https://www.openbell.ai/news/CNDT:1790768902602 2026-09-30T11:48:22.602Z daily 0.9 https://cdn.brandfetch.io/CNDT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Conduent Outlines Three-Year Strategy At Investor Day, Focusing On Healthcare And Financial Operations In Government And Commercial Segments openbell Financial News https://www.openbell.ai/news/PATH:1790768840074 2026-09-30T11:47:20.074Z daily 0.9 https://cdn.brandfetch.io/PATH/w/400/h/400?c=1idopYfmtR7ZKg8QMud UiPath Expands Partnership With BDO To Build Agentic AI Solutions UiPath, Inc. (NYSE: PATH) has expanded its partnership with BDO USA to develop AI and business orchestration solutions focused on enterprise functions such as risk management and compliance. The collaboration aims to create AI agents that automate internal audit processes, enhancing efficiency in monitoring controls and testing. As of the latest premarket session, UiPath shares are up approximately 0.49% to $12.38, though the stock remains 12.8% below its 20-day moving average. Analysts have a consensus Hold rating on the stock, with an average price target of $15.57. https://www.openbell.ai/news/VBIO:1790768808279 2026-09-30T11:46:48.279Z daily 0.9 https://cdn.brandfetch.io/VBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Valion Bio Announces Completion Of Needle-Free Oral Formulation Of Radiation Injury Drug Entolimod With Shear Kershman Laboratories openbell Financial News https://www.openbell.ai/news/IMNM:1790768790367 2026-09-30T11:46:30.367Z daily 0.9 https://cdn.brandfetch.io/IMNM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors Immunome, Inc. (NASDAQ: IMNM) has received FDA clearance for its Investigational New Drug application for IM-1340, an antibody-drug conjugate aimed at treating advanced solid tumors. This marks a significant step for the clinical-stage oncology company in its efforts to develop targeted cancer therapies. https://www.openbell.ai/news/CVCO:1790768750102 2026-09-30T11:45:50.102Z daily 0.9 https://cdn.brandfetch.io/CVCO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oppenheimer Initiates Coverage On Cavco Indus with Outperform Rating, Announces Price Target of $720 Oppenheimer analyst Tyler Batory has initiated coverage on Cavco Industries (NASDAQ: CVCO) with an Outperform rating. The firm has set a price target of $720 for the company's stock. https://www.openbell.ai/news/MORN:1790768742325 2026-09-30T11:45:42.325Z daily 0.9 https://cdn.brandfetch.io/MORN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Morningstar Plans To Shift Global Headquarters To Chicago's Thompson Center Morningstar, Inc. (NASDAQ: MORN) has announced plans to relocate its global headquarters to the Thompson Center in Chicago. The company will also invest an additional $5 million over five years to support local nonprofits, reinforcing its commitment to the city. This move aims to enhance Chicago's economic vitality and workforce development. https://www.openbell.ai/news/DOW:1790768486755 2026-09-30T11:41:26.755Z daily 0.9 https://cdn.brandfetch.io/DOW/w/400/h/400?c=1idopYfmtR7ZKg8QMud Citigroup Downgrades Dow to Neutral, Lowers Price Target to $30 Citigroup analyst Patrick Cunningham has downgraded Dow (NYSE: DOW) from a Buy rating to Neutral. Additionally, the price target for the stock has been reduced from $35 to $30. https://www.openbell.ai/news/KMX:1790768370781 2026-09-30T11:39:30.781Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Columbus-ohiousa-April-24--2019-Carmax-I.jpg?width=250&height=187 CarMax Analysts Boost Their Forecasts After Upbeat Q2 Results CarMax Inc (NYSE: KMX) reported adjusted earnings of $1.16 per share for Q2, significantly surpassing the analyst estimate of 73 cents. Sales increased by 19.5% year-over-year to $7.88 billion, exceeding expectations of $6.98 billion. Retail used-vehicle sales rose 13.8% to 227,391 units, with comparable-store sales up 13%. Following the earnings announcement, analysts adjusted their price targets, with B of A Securities raising it from $45 to $50 and BNP Paribas increasing it from $33 to $48. https://www.openbell.ai/news/MBLY:1790768363807 2026-09-30T11:39:23.807Z daily 0.9 https://cdn.brandfetch.io/MBLY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Barclays Downgrades Mobileye Global to Equal-Weight, Lowers Price Target to $9 Barclays analyst Dan Levy has downgraded Mobileye Global (NASDAQ: MBLY) from Overweight to Equal-Weight. The price target for the stock has been reduced from $14 to $9. https://www.openbell.ai/news/FE:1790768290863 2026-09-30T11:38:10.863Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Experts-Criticize-Tariff-Plan.jpg?width=250&height=187 Wall Street's Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields Three utilities stocks with high dividend yields have been highlighted by analysts: FirstEnergy Corp (FE) with a 4.26% yield, Spire Inc (SR) at 4.30%, and AES Corp (AES) yielding 4.74%. FirstEnergy's price target was reduced from $52 to $49 by Morgan Stanley, while Spire's target was cut from $91 to $88. AES received CFIUS approval for its merger with Global Infrastructure Management. Analysts have maintained Overweight and Equal-Weight ratings across these stocks, indicating a generally positive outlook despite some target reductions. https://www.openbell.ai/news/SPY:1790768240958 2026-09-30T11:37:20.958Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Budget-Economy-And-Finance-Background-Wi.jpg?width=250&height=187 Moody’s Mark Zandi Warns Wall Street is 'Too Optimistic' About the American Consumer: 'I Am Getting More Nervous...' Mark Zandi, Chief Economist at Moody's Analytics, expressed concerns about consumer spending forecasts, citing wage stagnation, declining savings, and rising borrowing costs as key issues. He challenged the optimistic view of consumer resilience, stating that macroeconomic data does not support a strong outlook for lower- and middle-income households. Zandi highlighted that after-tax income adjusted for inflation is stagnant and noted the impact of high mortgage rates on consumers' financial flexibility. Meanwhile, the S&P 500 index has increased by 11.84% year-to-date, with mixed performance in ETFs tracking major indices. https://www.openbell.ai/news/TRAX:1790768197238 2026-09-30T11:36:37.238Z daily 0.9 https://cdn.brandfetch.io/TRAX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Canaccord Genuity Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $50 Canaccord Genuity analyst Edward Nash has initiated coverage on First Tracks (NASDAQ: TRAX) with a Buy rating. The firm has set a price target of $50 for the stock. https://www.openbell.ai/news/CNSY:1790768140540 2026-09-30T11:35:40.540Z daily 0.9 https://cdn.brandfetch.io/CNSY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cerenome Anticipates $1.55M In Payer Billings In Q3 Cerenome, Inc. (Nasdaq: CNSY) reported that its subsidiary, CNSide Diagnostics, LLC, anticipates $1.55 million in gross payer billings for Q3 2026 from 222 tests billed. The company is also making progress on securing Medicare coverage for its Tumor Cell Enumeration Test (TCE Test) and expanding its testing menu. Initial cash collections from these billings are expected in Q4 2026. https://www.openbell.ai/news/HON:1790768044571 2026-09-30T11:34:04.571Z daily 0.9 https://cdn.brandfetch.io/HON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Dangote Petroleum Refinery And Petrochemicals FZE Selects Honeywell To Provide Process Technologies, Licensing, Engineering Services, Proprietary Catalysts, Equipment And Digital Solutions For Planned 700K Barrel-Per-Day Refinery In Kenya Dangote Petroleum Refinery and Petrochemicals FZE has chosen Honeywell Technologies to provide essential services and technologies for its upcoming 700,000 barrel-per-day refinery in Kenya, which is set to be the world's largest single-train refinery. This partnership builds on nearly a decade of collaboration and is expected to accelerate the project's development by nearly two years. The refinery will utilize Honeywell's solutions to produce various fuels and will be capable of processing diverse crude oil grades, enhancing supply flexibility. https://www.openbell.ai/news/GSK:1790768036662 2026-09-30T11:33:56.662Z daily 0.9 https://cdn.brandfetch.io/GSK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wave Life Sciences Announces $12M Milestone As GSK Selects Liver Disease Candidate For Development openbell Financial News https://www.openbell.ai/news/CYTK:1790768018928 2026-09-30T11:33:38.928Z daily 0.9 https://cdn.brandfetch.io/CYTK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cytokinetics Begins ASPEN-HCM Study Evaluating MYQORZO In Adult Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Cytokinetics has initiated the ASPEN-HCM study to evaluate the safety and effectiveness of MYQORZO in adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). This multicenter, observational study, led by UCSF, aims to enroll approximately 400 patients over 12 to 36 months to generate real-world evidence on MYQORZO's clinical and economic impact. Key outcomes will include reductions in left ventricular ejection fraction and treatment discontinuations, alongside analyses of healthcare resource utilization and treatment patterns. https://www.openbell.ai/news/REKR:1790767982232 2026-09-30T11:33:02.232Z daily 0.9 https://cdn.brandfetch.io/REKR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Rekor Systems Awarded $1.4M Contract By Oregon Department Of Transportation For Connected In-Vehicle Alerts Program Rekor Systems, Inc. (NASDAQ: REKR) has been awarded a $1.4 million contract by the Oregon Department of Transportation for a statewide Connected In-Vehicle Alerts program. This program will utilize Rekor Command® and its Driver Connect feature to provide traffic information directly to drivers, building on the company's previous success in Las Vegas, where it delivered over 1.18 million in-vehicle alerts. The contract is subject to final negotiations and annual renewals after the second year. https://www.openbell.ai/news/JBL:1790767931216 2026-09-30T11:32:11.216Z daily 0.9 https://cdn.brandfetch.io/JBL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jabil Sees Q1 Adj EPS $3.80-$4.20 vs $3.60 Est; Sees Sales $10.600B-$11.400B vs $9.942B Est Jabil (NYSE: JBL) projects its Q1 adjusted earnings per share (EPS) to be between $3.80 and $4.20, exceeding the $3.60 analyst estimate. The company anticipates sales in the range of $10.600 billion to $11.400 billion, compared to the $9.942 billion expected by analysts. https://www.openbell.ai/news/META:1790767923239 2026-09-30T11:32:03.239Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/In-this-photo-illustration--the-Meta-Mus.jpg?width=250&height=187 Meta’s Next AI Gold Mine? Muse Targets 200 Million Small Businesses As Zuckerberg Eyes Fees, Subscriptions Meta Platforms Inc. is expanding its AI product Muse, targeting approximately 200 million small businesses by offering services like customer engagement and inventory management. Muse has become the most downloaded app on the App Store, and Meta is exploring monetization strategies, including fees for cost-saving assistance and potential subscription models. The company is integrating partners such as Shopify and Walmart to enhance Muse's functionality, while its shares were down 0.38% to $736.00 in premarket trading. https://www.openbell.ai/news/CAG:1790767899433 2026-09-30T11:31:39.433Z daily 0.9 https://cdn.brandfetch.io/CAG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Conagra Brands Q1 Adj. EPS $0.41 Beats $0.28 Estimate, Sales $2.596B Beat $2.589B Estimate Conagra Brands (NYSE:CAG) reported Q1 adjusted earnings per share of $0.41, surpassing the analyst estimate of $0.28 by 46.43%, and showing a 5.13% increase from $0.39 per share in the same quarter last year. The company's quarterly sales reached $2.596 billion, slightly exceeding the $2.589 billion estimate by 0.27%, although this reflects a 1.41% decline from $2.633 billion in the prior year. https://www.openbell.ai/news/JBL:1790767877420 2026-09-30T11:31:17.420Z daily 0.9 https://cdn.brandfetch.io/JBL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jabil Sees FY2027 Adj EPS $17.55 vs $16.80 Est; Sees Sales $44.500B vs $42.643B Est Jabil (NYSE: JBL) forecasts an adjusted EPS of $17.55 for FY2027, surpassing the analyst estimate of $16.80. The company also projects sales of $44.500 billion, exceeding the expected $42.643 billion. https://www.openbell.ai/news/USO:1790767855753 2026-09-30T11:30:55.753Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Iraq Deepens October Crude Price Discounts to as Much as $37' - Bloomberg Iraq has increased its crude oil price discounts for October, with reductions reaching up to $37 per barrel. This move is expected to impact the global oil market, potentially affecting prices and supply dynamics. The adjustments come amid ongoing fluctuations in crude oil demand and production levels. https://www.openbell.ai/news/JBL:1790767830976 2026-09-30T11:30:30.976Z daily 0.9 https://cdn.brandfetch.io/JBL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jabil Q4 Adj. EPS $4.40 Beats $4.06 Estimate, Sales $10.616B Beat $9.693B Estimate Jabil (NYSE: JBL) reported Q4 earnings with an adjusted EPS of $4.40, surpassing the analyst estimate of $4.06 by 8.37%, and reflecting a 33.74% increase from $3.29 per share year-over-year. The company's quarterly sales reached $10.616 billion, exceeding the $9.693 billion estimate by 9.52% and marking a 28.65% rise from $8.252 billion in the same quarter last year. https://www.openbell.ai/news/AZZ:1790767565797 2026-09-30T11:26:05.797Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Analyst-Woman-Working-With-Information-D.jpg?width=250&height=187 AZZ Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call AZZ Inc. (NYSE: AZZ) is set to report its second-quarter earnings on October 13, with analysts expecting earnings of $1.84 per share, an increase from $1.55 per share in the same period last year. The consensus revenue estimate is $463.44 million, up from $417.27 million reported last year. Following a strong first-quarter performance and an upward revision of its FY27 guidance, AZZ shares rose 0.1% to close at $135.29. https://www.openbell.ai/news/AAPL:1790767494606 2026-09-30T11:24:54.606Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Apple-Ios-18-Logo-Is-Displayed-In-An-Iph.jpg?width=250&height=187 Is Apple's Strategy Paying Off? Strong iPhone 18 Pro China Demand Sparks Revenue Upside Apple Inc. (NASDAQ: AAPL) has reported strong demand for its iPhone 18 Pro in China, achieving a 12% year-over-year growth during its initial sales days and capturing a 33% market share. Despite a general decline in China's smartphone sales, the premium-first strategy appears effective, with longer delivery times for Pro models indicating consumer preference for higher-end devices. Analysts have raised revenue estimates for Apple's iPhone segment, predicting that the upcoming foldable Duo could significantly impact market share and revenue growth. https://www.openbell.ai/news/CYN:1790767004663 2026-09-30T11:16:44.663Z daily 0.9 https://cdn.brandfetch.io/CYN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cyngn Announces ISO 27001 Security Certification For Its Autonomous Vehicle Fleet Management Platform openbell Financial News https://www.openbell.ai/news/TSM:1790766934960 2026-09-30T11:15:34.960Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/TSMC--Photo-by-Sundry-Photography-on-Shu.jpg?width=250&height=187 AI’s Semiconductor Boom Has a Clear Center of Gravity: Taiwan Semiconductor Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE: TSM) reported a 34% year-over-year revenue increase to $40.2 billion in Q2, capturing 42% of the Foundry 2.0 market. Analysts expect its revenue to grow by 43% in 2026, driven by tight demand for advanced-node and packaging capacity. The broader Foundry 2.0 market reached a record $96.6 billion, up 25% year-over-year, with Taiwan Semiconductor identified as the primary beneficiary of the AI semiconductor boom. Despite this, shares were down 0.49% to $454.72 in premarket trading. https://www.openbell.ai/news/MSLE:1790766785931 2026-09-30T11:13:05.931Z daily 0.9 https://cdn.brandfetch.io/MSLE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age Satellos Bioscience Inc. has completed enrollment for its BASECAMP Phase 2 clinical trial, which is assessing the efficacy of forazapadin in treating Duchenne muscular dystrophy in boys aged 7 to 10. Forazapadin is an oral small molecule drug aimed at enhancing muscle regeneration in patients with DMD and other degenerative muscle diseases. https://www.openbell.ai/news/CBLL:1790766624340 2026-09-30T11:10:24.340Z daily 0.9 https://cdn.brandfetch.io/CBLL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ceribell Says FDA Cleared Brain Monitoring Software Update With No Age Restriction, Expects Rollout In 1H 2027 openbell Financial News https://www.openbell.ai/news/CNTB:1790766571194 2026-09-30T11:09:31.194Z daily 0.9 https://cdn.brandfetch.io/CNTB/w/400/h/400?c=1idopYfmtR7ZKg8QMud Connect Biopharma Announces Topline Results From Its Global Phase 2 Study Evaluating Rademikibart As An Add-on Treatment For Acute Exacerbations In Adult Participants With Chronic Obstructive Pulmonary Disease And Type 2 Inflammation; Rademikibart Significantly Reduced The Rate Of Treatment Failure Compared To Placebo Through One Month By 81%; Rademikibart Significantly Reduced The Rate Of New Moderate To Severe COPD Exacerbations Through One Month By 85% Connect Biopharma announced positive topline results from its Phase 2 study of Rademikibart as an add-on treatment for acute exacerbations in adults with Chronic Obstructive Pulmonary Disease (COPD). The treatment reduced the rate of treatment failure by 81% and new moderate to severe COPD exacerbations by 85% compared to placebo over four weeks. Additionally, Rademikibart led to a 100% reduction in emergency department visits and hospital admissions for new exacerbations, and it was well tolerated with no new safety signals reported. https://www.openbell.ai/news/BMR:1790766570976 2026-09-30T11:09:30.976Z daily 0.9 https://cdn.brandfetch.io/BMR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Beamr Sees FY2026 Revenue Of $4.5M, Up Around 50%; Announces Three-Year License Renewal With Unnamed Streaming Platform openbell Financial News https://www.openbell.ai/news/JBIO:1790766499841 2026-09-30T11:08:19.841Z daily 0.9 https://cdn.brandfetch.io/JBIO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jade Biosciences Says Dermatomyositis Candidate JADE301 Showed About 25-Day Half-Life In Primates; Expects Phase 1 Start In Q4 2026 openbell Financial News https://www.openbell.ai/news/SOTK:1790766385527 2026-09-30T11:06:25.527Z daily 0.9 https://cdn.brandfetch.io/SOTK/w/400/h/400?c=1idopYfmtR7ZKg8QMud Sono-Tek Announces Nearly $7.2M In Orders From Unnamed Clean Energy Customer For 10 Systems, Mostly For FY2028 Delivery openbell Financial News https://www.openbell.ai/news/TLSA:1790766331570 2026-09-30T11:05:31.570Z daily 0.9 https://cdn.brandfetch.io/TLSA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tiziana Life Sciences Announces Submission Of FDA Orphan Drug Designation Request For Foralumab In Multiple System Atrophy openbell Financial News https://www.openbell.ai/news/TLS:1790766264437 2026-09-30T11:04:24.437Z daily 0.9 https://cdn.brandfetch.io/TLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tiziana Life Sciences Announces Submission Of FDA Orphan Drug Designation Request For Foralumab In Multiple System Atrophy openbell Financial News https://www.openbell.ai/news/KLRA:1790766247789 2026-09-30T11:04:07.789Z daily 0.9 https://cdn.brandfetch.io/KLRA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028 Kailera Therapeutics, Inc. (NASDAQ: KLRA) has completed enrollment in its KaiNETIC global Phase 3 clinical program, which includes three trials assessing ribupatide injection (KAI-9531) for obesity treatment. This investigational drug targets individuals with a BMI of 35 kg/m² or higher. Topline data from the trials is now anticipated in mid-2028. https://www.openbell.ai/news/TE:1790766200996 2026-09-30T11:03:20.996Z daily 0.9 https://cdn.brandfetch.io/TE/w/400/h/400?c=1idopYfmtR7ZKg8QMud T1 Energy Finds Another $50 Million for Its Big Texas Solar Ambitions T1 Energy Inc. (NYSE: TE) has raised an additional $50 million through a private placement of convertible senior notes to fund its G2_Austin solar cell manufacturing facility in Texas. This financing increases the total principal amount of convertible notes to $170 million, with a maturity date of August 1, 2031. The company plans to use the funds for construction and infrastructure development related to Phase 1 of the project, with gross proceeds expected to be around $50.4 million before fees. T1 Energy's stock was up 0.53% to $3.79 in premarket trading. https://www.openbell.ai/news/TE:1790766191843 2026-09-30T11:03:11.843Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Solar-Panels-City-At-China.jpg?width=250&height=187 T1 Energy Finds Another $50 Million for Its Big Texas Solar Ambitions T1 Energy Inc. (NYSE: TE) has raised an additional $50 million through a private placement of convertible senior notes to fund its G2_Austin solar cell manufacturing facility in Texas. This financing, which is expected to close on September 30, will increase the total outstanding amount of convertible notes to $170 million, with a maturity date of August 1, 2031. The company plans to use the funds for construction and infrastructure development related to Phase 1 of the project. T1 Energy's stock was trading at $3.79, up 0.53% in premarket trading. https://www.openbell.ai/news/NRXP:1790766155408 2026-09-30T11:02:35.408Z daily 0.9 https://cdn.brandfetch.io/NRXP/w/400/h/400?c=1idopYfmtR7ZKg8QMud NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects Agency NRx Defense Systems, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), has been awarded an initial contract worth $11,177,757.27 by the Defense Advanced Research Projects Agency (DARPA) for its SPARC-TMS trial. This trial aims to evaluate a treatment protocol for Treatment Resistant Depression using Robotic Neuronavigated Transcranial Magnetic Stimulation (TMS) combined with the investigational drug NRX-101. The trial has received FDA approval and will be conducted at several institutions, including Harvard Medical School’s McLean Hospital and Arizona State University, with plans to expand to military hospitals. https://www.openbell.ai/news/FDS:1790766025778 2026-09-30T11:00:25.778Z daily 0.9 https://cdn.brandfetch.io/FDS/w/400/h/400?c=1idopYfmtR7ZKg8QMud FactSet Research Systems Q4 Adj. EPS $4.52 Beats $4.33 Estimate, Sales $634.698M Beat $629.829M Estimate FactSet Research Systems (NYSE:FDS) reported Q4 adjusted earnings per share of $4.52, surpassing the analyst estimate of $4.33 by 4.15%, and reflecting an 11.6% increase from $4.05 per share in the same period last year. The company's quarterly sales reached $634.698 million, exceeding the consensus estimate of $629.829 million by 0.77%, and marking a 6.33% increase from $596.901 million in the prior year. https://www.openbell.ai/news/NVDA:1790766008108 2026-09-30T11:00:08.108Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/Nvidia.jpg?width=250&height=187 Dan Ives Calls Physical AI Nvidia’s 'Holy Grail' — This ETF Is Already in the Trade NVIDIA Corp. (NASDAQ: NVDA) reported over $9 billion in revenue from its physical AI segment in the past year, which includes applications in robotics and autonomous systems. Analyst Dan Ives highlighted this area as a significant growth opportunity, potentially expanding NVIDIA's market beyond data centers into sectors like manufacturing and healthcare. Additionally, NVIDIA has announced a record $150 billion increase to its share repurchase authorization, further positioning itself as a key player in the emerging robotics and automation cycle. https://www.openbell.ai/news/NICE:1790765979350 2026-09-30T10:59:39.350Z daily 0.9 https://cdn.brandfetch.io/NICE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Oppenheimer Upgrades NICE to Outperform, Announces $150 Price Target Oppenheimer analyst Timothy Horan has upgraded NICE (NASDAQ: NICE) from a rating of Perform to Outperform. Along with the upgrade, Horan has set a price target of $150 for the stock. https://www.openbell.ai/news/TE:1790765944885 2026-09-30T10:59:04.885Z daily 0.9 https://cdn.brandfetch.io/TE/w/400/h/400?c=1idopYfmtR7ZKg8QMud T1 Energy Finds Another $50 Million for Its Big Texas Solar Ambitions T1 Energy Inc. (NYSE: TE) has raised an additional $50 million through a private placement of convertible senior notes to fund its G2_Austin solar cell manufacturing facility in Texas. This financing increases the total principal amount of convertible notes to $170 million, with a maturity date of August 1, 2031. The company plans to use the proceeds for construction and infrastructure development related to Phase 1 of the project. T1 Energy's stock was up 0.53% to $3.79 in premarket trading. https://www.openbell.ai/news/NEXR:1790765940870 2026-09-30T10:59:00.870Z daily 0.9 https://cdn.brandfetch.io/NEXR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Nexera Technologies And Unit Fort Technology Plan To Expand Logia USA Operations In The U.S. Following Completion Of Previously Announced Acquisition Nexera Technologies and Unit Fort Technology plan to expand Logia USA operations in the U.S. after Fort completed the acquisition of 50.1% of Logia USA for approximately US$125,000 in common shares. Logia USA, which has not yet begun sales, has secured an exclusive five-year license to commercialize automated fuel maintenance systems developed by Logia Israel. Additionally, Fort has established a credit facility of up to US$2.0 million to support Logia USA's market entry and growth, focusing on the data center sector. https://www.openbell.ai/news/META:1790765887002 2026-09-30T10:58:07.002Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/30/In-this-photo-illustration--the-Meta-Mus.jpg?width=250&height=187 Mark Zuckerberg's Muse Could Charge You for Saving You Money — META President Reveals AI Agent's Potential Monetization Model Meta Platforms Inc. (NASDAQ: META) is considering transaction fees and paid subscriptions as monetization strategies for its AI service, Muse, according to President Dina Powell McCormick. Muse, which has reached the number one spot on the App Store, helps users save money and may implement fees based on user engagement. The company has launched Muse for small businesses, allowing them to automate various tasks, and is integrating the tool with partners like Shopify and Salesforce. As of the latest trading session, META stock was down 0.62% over the past year, but up 11.92% year-to-date. https://www.openbell.ai/news/CLS:1790765380870 2026-09-30T10:49:40.870Z daily 0.9 https://cdn.brandfetch.io/CLS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Initiates Coverage On Celestica with Outperform Rating, Announces Price Target of $520 Bernstein analyst Daniel Zhu has initiated coverage on Celestica (NYSE: CLS) with an Outperform rating. The analyst has set a price target of $520 for the company's stock. https://www.openbell.ai/news/LITE:1790765313965 2026-09-30T10:48:33.965Z daily 0.9 https://cdn.brandfetch.io/LITE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Bernstein Initiates Coverage On Lumentum Holdings with Outperform Rating, Announces Price Target of $1220 Bernstein analyst Daniel Zhu has initiated coverage on Lumentum Holdings (NASDAQ: LITE) with an 'Outperform' rating. The analyst has set a price target of $1220 for the company's stock. https://www.openbell.ai/news/NVDA:1790765275358 2026-09-30T10:47:55.358Z daily 0.9 https://cdn.brandfetch.io/NVDA/w/400/h/400?c=1idopYfmtR7ZKg8QMud Jacobs Selected By Nvidia To Deploy Its Data Center Digital Twin For A Large-Scale U.S. R&D Facility Under Three-Year Software-As-A-Service Deal; Terms Not Disclosed Jacobs has been selected by Nvidia to implement its Data Center Digital Twin for a large-scale R&D facility under a three-year Software-as-a-Service agreement, with terms not disclosed. This digital twin environment aims to enhance operational planning and facility performance by integrating engineering models and live data. The solution will support various predictive and simulation-driven use cases, including energy forecasting and predictive maintenance. This partnership builds on Jacobs' previous work with Nvidia in advancing digital twin technology for AI infrastructure.